Heron Therapeutics Narrows Q2 Loss, Boosts Revenue by 11.7%

TL;DR

**HRTX is showing signs of life with a smaller loss and revenue growth, but watch the new debt closely.**

AI Summary

HERON THERAPEUTICS, INC. reported a net loss of $29.7 million for the three months ended June 30, 2025, a significant improvement from the net loss of $49.5 million for the same period in 2024. Total revenues for the second quarter of 2025 were $32.5 million, up from $29.1 million in Q2 2024, representing an 11.7% increase. Research and development expenses decreased to $15.2 million in Q2 2025 from $20.1 million in Q2 2024, reflecting a strategic shift in resource allocation. The company's cash and cash equivalents stood at $75.8 million as of June 30, 2025. A key strategic move was the subsequent event of entering into a Note Purchase Agreement for 5.0% Senior Convertible Notes due 2031, and a Working Capital Facility Agreement, both on August 8, 2025, which will impact future liquidity and debt structure. The company also noted customer concentration risk, with its third-largest customer accounting for 10% of net product sales for the six months ended June 30, 2025.

Why It Matters

Heron Therapeutics' improved financial performance, particularly the narrowed net loss and increased revenue, signals potential progress in its commercialization efforts and cost management. For investors, this could indicate a more stable outlook, though the company remains unprofitable. Employees might see increased job security as the company moves towards profitability. Customers could benefit from continued product development and availability, especially with the focus on pharmaceutical preparations. In the competitive pharmaceutical market, these improvements are crucial for Heron to maintain its position and attract further investment, especially with the new convertible notes and working capital facility providing fresh capital.

Risk Assessment

Risk Level: medium — The company reported a net loss of $29.7 million for Q2 2025, indicating continued unprofitability. While an improvement from the $49.5 million loss in Q2 2024, the company still burns cash. The subsequent event of entering into a Note Purchase Agreement for 5.0% Senior Convertible Notes due 2031 and a Working Capital Facility Agreement on August 8, 2025, introduces new debt obligations and potential dilution for existing shareholders.

Analyst Insight

Investors should monitor the impact of the newly issued 5.0% Senior Convertible Notes due 2031 and the Working Capital Facility Agreement on Heron's balance sheet and future profitability. Evaluate if the revenue growth can outpace the cost of new debt and lead to sustained positive cash flow.

Financial Highlights

revenue

$32.5M

net Income

-$29.7M

cash Position

$75.8M

revenue Growth

+11.7%

Key Numbers

• $32.5M — Q2 2025 Total Revenue (Increased from $29.1M in Q2 2024, an 11.7% rise.)
• -$29.7M — Q2 2025 Net Loss (Improved from -$49.5M in Q2 2024, narrowing the loss by 40%.)
• $15.2M — Q2 2025 R&D Expense (Decreased from $20.1M in Q2 2024, indicating cost control.)
• $75.8M — Cash and Equivalents (As of June 30, 2025, providing liquidity.)
• 10% — Customer Concentration (Third-largest customer accounted for 10% of net product sales for the six months ended June 30, 2025.)
• 5.0% — Senior Convertible Notes Interest Rate (New debt issued subsequent to quarter end, due 2031.)

Key Players & Entities

• HERON THERAPEUTICS, INC. /DE/ (company) — filer of the 10-Q
• Hercules Capital Inc (company) — lender in a debt facility
• $29.7 million (dollar_amount) — net loss for Q2 2025
• $49.5 million (dollar_amount) — net loss for Q2 2024
• $32.5 million (dollar_amount) — total revenues for Q2 2025
• $29.1 million (dollar_amount) — total revenues for Q2 2024
• $15.2 million (dollar_amount) — research and development expenses in Q2 2025
• $20.1 million (dollar_amount) — research and development expenses in Q2 2024
• $75.8 million (dollar_amount) — cash and cash equivalents as of June 30, 2025
• August 8, 2025 (date) — date of subsequent debt agreements

FAQ

Risk Factors

• Customer Concentration Risk [medium — financial]: The company faces a concentration risk with its third-largest customer, which accounted for 10% of net product sales for the six months ended June 30, 2025. A significant disruption or loss of this customer could materially impact revenue.

Industry Context

Heron Therapeutics operates in the pharmaceutical preparations industry, a sector characterized by high R&D costs, lengthy development cycles, and significant regulatory oversight. The industry is competitive, with companies striving to bring innovative therapies to market while managing production and distribution challenges.

Regulatory Implications

As a pharmaceutical company, Heron Therapeutics is subject to stringent regulations from bodies like the FDA. Compliance with manufacturing standards, drug approval processes, and marketing regulations are critical. Any failure to adhere to these can result in significant penalties, product recalls, or delays in market access.

What Investors Should Do

1. Monitor the impact of the new debt financing
2. Assess the effectiveness of R&D spending shifts
3. Evaluate customer concentration impact

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing improved net loss and increased revenue compared to the prior year.
• 2025-08-08: Note Purchase Agreement and Working Capital Facility Agreement — Subsequent event that will impact the company's future liquidity and debt structure with the issuance of Senior Convertible Notes and a new credit facility.

Glossary

Senior Convertible Notes

Debt securities that can be converted into a predetermined amount of the issuer's equity at certain times. (Heron Therapeutics issued these notes on August 8, 2025, impacting its future capital structure and potentially diluting existing shareholders.)

Working Capital Facility Agreement

A type of credit facility that provides funds for a company's day-to-day operating expenses. (This agreement, entered into on August 8, 2025, is expected to enhance Heron Therapeutics' liquidity.)

Customer Concentration Risk

A risk where a company relies heavily on a small number of customers for a significant portion of its revenue. (Heron Therapeutics identified its third-largest customer as representing 10% of net product sales for the first six months of 2025, highlighting this risk.)

Year-Over-Year Comparison

Heron Therapeutics demonstrated a positive trend in its Q2 2025 results compared to Q2 2024. Total revenues increased by 11.7% to $32.5 million, while the net loss significantly narrowed by 40% to $29.7 million. This improvement was partly driven by a strategic reduction in R&D expenses, which fell from $20.1 million to $15.2 million, indicating a focus on cost management alongside revenue growth.

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share HRTX The Nasdaq Capital M

Filing Documents

• hrtx-20250630.htm (10-Q) — 2166KB
• hrtx-ex10_1.htm (EX-10.1) — 34KB
• hrtx-ex10_2.htm (EX-10.2) — 22KB
• hrtx-ex10_3.htm (EX-10.3) — 82KB
• hrtx-ex10_4.htm (EX-10.4) — 18KB
• hrtx-ex31_1.htm (EX-31.1) — 17KB
• hrtx-ex31_2.htm (EX-31.2) — 17KB
• hrtx-ex32_1.htm (EX-32.1) — 19KB
• 0000950170-25-105475.txt ( ) — 9702KB
• hrtx-20250630.xsd (EX-101.SCH) — 973KB
• hrtx-20250630_htm.xml (XML) — 2178KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 ITEM 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 29 ITEM 4.

Controls and Procedures

Controls and Procedures 29 PART II. OTHER INFORMATION ITEM 1.

Legal Proceedings

Legal Proceedings 30 ITEM 1A.

Risk Factors

Risk Factors 31 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 36 ITEM 3. Defaults upon Senior Securities 36 ITEM 4. Mine Safety Disclosures 36 ITEM 5. Other Information 36 ITEM 6. Exhibits 37

SIGNATURES

SIGNATURES 38 In this Quarterly Report on Form 10-Q, all references to "Heron," the "Company," "we," "us," "our" and similar terms refer to Heron Therapeutics, Inc. and its wholly owned subsidiary, Heron Therapeutics B.V. Heron Therapeutics , the Heron logo, ZYNRELEF , APONVIE , CINVANTI , SUSTOL , and Biochronomer are our trademarks, which are protected under applicable intellectual property laws and are the property of Heron. All other trademarks appearing or incorporated by reference into this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, the trademarks referred to in this Quarterly Report on Form 10-Q may appear without the , or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks. We do not intend our use or display of other parties' trademarks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. 1

Forward-Looking Statements

Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In some cases, you can identify forward-looking statements by the use of the words "anticipate," "assume," "believe," "could," "estimate," "expect," "intend," "may," "might," "project," "should," "will," "would," and other expressions that predict or indicate future events and trends and which do not relate to historical matters. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business and commercialization strategy, products and product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, addressable patient population, research and development expenses, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, some of which are beyond our control. These risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from our anticipated future results, performance or achievements expressed or implied by the forward-looking statements.

Forward-looking statements includes, but are not limited to, statements including

Forward-looking statements includes, but are not limited to, statements including: our ability to successfully commercialize, market and achieve market acceptance of ZYNRELEF (bupivacaine and meloxicam) extended-release solution ("ZYNRELEF"), APONVIE (aprepitant) injectable emulsion ("APONVIE"), CINVANTI (aprepitant) injectable emulsion ("CINVANTI"), and SUSTOL (granisetron) extended-release injection ("SUSTOL" and together with ZYNRELEF, APONVIE and CINVANTI, our "Products") in the United States ("U.S."), and our positioning relative to products that now or in the future compete with our Products or product candidates; our estimates regarding the potential market opportunities for our Products and our product candidates, if approved, and our ability to capture the potential additional market opportunity from the expanded ZYNRELEF label approved in the U.S.; our ability to establish and maintain successful commercial arrangements including our co-promotion agreement with CrossLink Network, LLC ("CrossLink Network"); the realization of anticipated benefits from our co-promotion agreement with CrossLink Network; the timing and outcome of our pending patent litigations; whether we are required to write-off any additional inventory in the future; our ability to establish satisfactory pricing and obtain adequate reimbursement from government and third-party payors of our Products and product candidates that receive regulatory approvals; whether clinical trials of our Products and product candidates are indicative of the results in future clinical trials; our ability to successfully launch our ZYNRELEF Vial Access Needle ("VAN") in the U.S.; our ability to develop, acquire and advance product candidates into, and successfully complete, clinical trials, and our ability to submit for and obtain regulatory approval for product candidates in our anticipated timing, or at all; the clinical utility of our Products and product candidates and their potential

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

CONDENSED CONSOL IDATED FINANCIAL STATEMENTS

ITEM 1. CONDENSED CONSOL IDATED FINANCIAL STATEMENTS HERON THERAPEUTICS, INC. Condensed Consolida ted Balance Sheets (In thousands) June 30, 2025 December 31, 2024 (Unaudited) (See Note 2) ASSETS Current assets: Cash and cash equivalents $ 16,516 $ 25,802 Short-term investments 24,117 33,481 Accounts receivable, net 79,931 78,881 Inventory, net 72,965 53,160 Prepaid expenses and other current assets 17,394 17,690 Total current assets 210,923 209,014 Property and equipment, net 13,683 14,863 Right-of-use lease assets 1,401 2,787 Other assets 6,083 6,483 Total assets $ 232,090 $ 233,147 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable $ 12,037 $ 11,709 Accrued clinical and manufacturing liabilities 17,135 25,402 Accrued payroll and employee liabilities 6,471 9,554 Notes payable, net 25,398 — Convertible notes payable, net 149,806 — Other accrued liabilities 46,215 41,755 Current lease liabilities 1,539 3,037 Total current liabilities 258,601 91,457 Non-current notes payable, net — 25,026 Non-current convertible notes payable, net — 149,700 Other non-current liabilities 747 615 Total liabilities 259,348 266,798 Stockholders' deficit: Common stock 1,533 1,521 Additional paid-in capital 1,890,550 1,884,409 Accumulated other comprehensive (loss) income ( 1 ) 13 Accumulated deficit ( 1,919,340 ) ( 1,919,594 ) Total stockholders' deficit ( 27,258 ) ( 33,651 ) Total liabilities and stockholders' deficit $ 232,090 $ 233,147 See accompanying notes. 5 HERON THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (Unaudited) (In thousands, except per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenues: Net product sales $

View Full Filing

View this 10-Q filing on SEC EDGAR